Leerink Partners Remains a Buy on Century Therapeutics (IPSC)
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday and set a price ...
Fintel on MSN1d
Leerink Partners Upgrades Genmab A (GMAB)
Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market ...
Nkarta (NKTX) Gets a Buy from Leerink Partners
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.
Leerink raises Genmab stock rating to outperform, PT steady at $27
Leerink Partners analyst shifted the rating for Genmab A/S (NASDAQ:GMAB) stock from Market Perform to Outperform, maintaining a price target (PT) of $27.00. The upgrade reflects a positive long-term ...
Ex-Goldman Banker Advances Some Pay Claims Against Leerink Firm
An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...
Leerink Partners Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Outperform
Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...
Leerink Partners Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $150.00
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective boosted by analysts at Leerink Partners from $110 ...
Thryv Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference in Miami, FL
Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...